TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01309438

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban (normal renal function)
Description: One 10 mg tablet of rivaroxaban taken orally (by mouth) on Day 1 of Treatment Period 1; One 10 mg tablet of rivaroxaban taken orally on Day 5 of Treatment Period 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban (mild and moderate renal impairment)
Description: One 10 mg tablet of rivaroxaban taken orally (by mouth) on Day 1 of Treatment Period 1; One 5 mg tablet of rivaroxaban taken orally on Day 5 of Treatment Period 2; One 10 mg tablet of rivaroxaban taken orally on Day 5 of Treatment Period 3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban (mild and moderate renal impairment)
Description: One 10 mg tablet of rivaroxaban taken orally (by mouth) on Day 1 of Treatment Period 1; One 5 mg tablet of rivaroxaban taken orally on Day 5 of Treatment Period 2; One 10 mg tablet of rivaroxaban taken orally on Day 5 of Treatment Period 3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erythromycin (normal renal function)
Description: One 500 mg tablet taken orally (by mouth) three times daily on Days 1 to 6 of Treatment Period 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erythromycin (mild and moderate renal function)
Description: One 500 mg tablet taken orally (by mouth) three times daily on Days 1 to 6 of Treatment Periods 2 and 3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erythromycin (mild and moderate renal function)
Description: One 500 mg tablet taken orally (by mouth) three times daily on Days 1 to 6 of Treatment Periods 2 and 3
Study: NCT00411736

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Study medication, azithromycin or placebo
Description: Granulate for syrup in the group under 8 years, 40 mg/ml. Dose: 5 mg/kg/day in one daily dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin or placebo tablets
Description: Tablets of 250 mg, azithromycin or placebo. Dosage: 1 tablet every other day for participants with a weight less than 40 kg´s. 1 tablet every day for participants weighing 40 kg´s or more.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin or placebo tablets
Description: Tablets of 250 mg, azithromycin or placebo. Dosage: 1 tablet every other day for participants with a weight less than 40 kg´s. 1 tablet every day for participants weighing 40 kg´s or more.
Study: NCT04005950

Intervention type: DEVICE
Intervention: Scalpel Bougie technique
Description: ScalpelCric Set

Intervention type: DEVICE
Intervention: Scalpel Bougie technique
Description: ScalpelCric Set

Intervention type: DEVICE
Intervention: modified Scalpel Bougie technique
Description: ScalpelCric Set plus speculum

Intervention type: DEVICE
Intervention: modified Scalpel Bougie technique
Description: ScalpelCric Set plus speculum
Study: NCT02862223

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Neoprinol
Study: NCT00574431

Intervention type: OTHER
Group type: OTHER
Intervention: Data Collection
Description: Collection of patient data before implementation of a nutritional management protocol

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Nutritional management protocol
Description: Collection of patient data after implementation of a nutritional management protocol
Study: NCT02033772

Intervention type: PROCEDURE
Intervention: Thoracoscopic surgery
Study: NCT02662985

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AIN457 (secukinumab)
Description: Is a recombinant monoclonal antibody which neutralizes the activity of IL-17A, and has been shown to be effective in treating patients with moderate-to-severe plaque psoriasis.~Secukinumab 150 mg provided in 1 mL pre filled syringes (PFS) for s.c. injection. The 300 mg dose was administered as 2 × PFS injections.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: AIN457 (secukinumab)
Description: Is a recombinant monoclonal antibody which neutralizes the activity of IL-17A, and has been shown to be effective in treating patients with moderate-to-severe plaque psoriasis.~Secukinumab 150 mg provided in 1 mL pre filled syringes (PFS) for s.c. injection. The 300 mg dose was administered as 2 × PFS injections.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Secukinumab placebo was provided in a 1 mL PFS for s.c. injection.
Study: NCT00050791

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leptin
Description: Leptin is an adipocyte hormone that functions as an afferent signal in a feedback loop regulating body weight

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Very Low Calorie Diet
Description: placebo injections
Study: NCT03302208

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pregabalin
Description: Pregabalin capsule 150 mg oral

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT02484612

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: acute exercise

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: acute exercise
Study: NCT04097171

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diet
Description: Participants will consume each diet for 14 days in a crossover design.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diet
Description: Participants will consume each diet for 14 days in a crossover design.
Study: NCT03110601

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Control - Conventional SCS
Description: Conventional SCS Parameters

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Test - Stimgenics SCS
Description: Stimgenics SCS Parameters
Study: NCT02984774

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cystectomy
Description: Segment of cystic wall from the patients for planned cystectomy was taken after operation and was preserved at -80º Celsius for further analysis

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cystectomy
Description: Segment of cystic wall from the patients for planned cystectomy was taken after operation and was preserved at -80º Celsius for further analysis

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Endometrial sampling
Description: Endometrial sampling was performed at the same operation with the planned operation for the main indication and was preserved at -80º Celsius for further analysis

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endometrial sampling
Description: Endometrial sampling was performed at the same operation with the planned operation for the main indication and was preserved at -80º Celsius for further analysis

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endometrial sampling
Description: Endometrial sampling was performed at the same operation with the planned operation for the main indication and was preserved at -80º Celsius for further analysis

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Peripheric blood sampling
Description: 4 cc peripheric venous blood was sampled into the EDTA(Ethylenediaminetetraacetic acid)-containing tubes during catheterization for anesthesia was preserved at 4º Celsius for further analysis

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peripheric blood sampling
Description: 4 cc peripheric venous blood was sampled into the EDTA(Ethylenediaminetetraacetic acid)-containing tubes during catheterization for anesthesia was preserved at 4º Celsius for further analysis

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peripheric blood sampling
Description: 4 cc peripheric venous blood was sampled into the EDTA(Ethylenediaminetetraacetic acid)-containing tubes during catheterization for anesthesia was preserved at 4º Celsius for further analysis

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Ovarian tissue sampling
Description: 2cm linear tissue sample from ovarian cortex was performed at the same operation with the planned operation for the main indication and was preserved at -80º Celsius for further analysis
Study: NCT04171557

Intervention type: BEHAVIORAL
Intervention: Bicycling
Description: Total bicycling is reported in categories of: (0 - reference), (\>0 to \<60), (≤60 to \>150), (≤150 to \< 300) and (≥300) minutes/week
Study: NCT06044467

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo - Study Part One
Description: Placebo Comparator

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo - Study Part Two
Description: Placebo Comparator
Study: NCT04521530

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immediate functional implant loading
Description: Patients will undergo implant placement and a minimum of 35 Ncm reading with the graded torque wrench. Temporary crowns in functional occlusion were cemented.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immediate non functional implant loading
Description: implant will be placed into the site following the manufacturer's protocol making sure to have a minimum of 35 Newton centimeter reading with the degraded torque wrench. Non-functional temporary crowns were cemented.
Study: NCT03262935

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: (vic-)trastuzumab duocarmazine
Description: Intravenous SYD985, Q3W

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Physician's choice
Description: See drug label
Study: NCT02520908

Intervention type: PROCEDURE
Intervention: HSCT
Description: Hematopoietic stem cell transplantation

Intervention type: OTHER
Intervention: Standard Care
Study: NCT00557206

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin and Docetaxel
Description: Chemotherapy~Oxaliplatin 130mg/m2 on day 1; and Docetaxel 75mg/m2 on day 1; every 21 days.
Study: NCT00373386

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: growth hormone
Description: Growth Hormone treatment
Study: NCT04414995

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paracetamol injection and Ibuprofen injection
Description: Use of combination acetaminophen and ibuprofen to reduce morphine requirement inpatient after Total knee arthroplasty

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paracetamol injection and normal saline
Description: Use of paracetamol and normal saline to reduce morphine requirement inpatient after Total knee arthroplasty

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen Injection and normal saline
Description: Use of ibuprofen and normal saline to reduce morphine requirement inpatient after Total knee arthroplasty
Study: NCT04280497

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Administration procedures
Description: Hydrocortisone hemisuccinate / hydrocortisone placebo will be given as 50 mg intravenous bolus every 6 hours;~9 alpha fludrocortisone / 9 alpha fludrocortisone placebo will be given as a 50 μg tablet via a nasogastric tube once per day in the morning.~Study drugs will be started immediately after randomization (day 0 of the study), until discharge from ICU for a maximal duration of 7 days. Study drugs will be stopped without tapering off.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Administration procedures
Description: Hydrocortisone hemisuccinate / hydrocortisone placebo will be given as 50 mg intravenous bolus every 6 hours;~9 alpha fludrocortisone / 9 alpha fludrocortisone placebo will be given as a 50 μg tablet via a nasogastric tube once per day in the morning.~Study drugs will be started immediately after randomization (day 0 of the study), until discharge from ICU for a maximal duration of 7 days. Study drugs will be stopped without tapering off.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Administration procedures
Description: Hydrocortisone hemisuccinate / hydrocortisone placebo will be given as 50 mg intravenous bolus every 6 hours;~9 alpha fludrocortisone / 9 alpha fludrocortisone placebo will be given as a 50 μg tablet via a nasogastric tube once per day in the morning.~Study drugs will be started immediately after randomization (day 0 of the study), until discharge from ICU for a maximal duration of 7 days. Study drugs will be stopped without tapering off.
Study: NCT03119831

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: C31G
Description: Rinsing with 15ml for one minute twice daily for 14 days
Study: NCT02767843

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: continuous negative external pressure (cNEP)
Description: soft silicone collar placed on the anterior neck, to which a negative pressure is introduced
Study: NCT03340688

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cervical cerclage
Description: Cervical cerclage indicated by short cervix ≤15mm
Study: NCT02024412

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: monosialotetrahexosylganglioside Sodium
Description: it is a component extract from pig's brain,shenjie is the brand name

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: saline of the same appearance as monosialotetrahexosylganglioside Sodium
Study: NCT02692196

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Real-time fMRI neurofeedback from Turbo Brain voyager (TBV) 3.2

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Real-time fMRI neurofeedback from Turbo Brain voyager (TBV) 3.2
Study: NCT02403544

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: IGRT
Description: IGRT: 45 to 54Gy, 1.8-3Gy per fraction.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine: by oral, D1-14, every 21 days, 600mg/m2 bid per day in level 1, and then escalated every another dose level.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Oxaliplatin: intravenously, D1 and D8, every 21 days, 30mg/m2 per day in level 1, and then escalated every another dose level.
Study: NCT03852030

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Text or email message
Description: Text or email messages sent to research participants

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Text or email message
Description: Text or email messages sent to research participants
Study: NCT02481414

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PepCan
Description: 50 μg peptide + 0.3 mL Candin® per dose administered intradermally in the extremities

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Candin®
Description: 0.3 mL Candin® per dose administered intradermally in the extremities
Study: NCT01513343

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parent and child groups focused on self-regulation of eating
Study: NCT00845104

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine phosphate
Description: Given IV
Study: NCT04280497

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Administration procedures
Description: Hydrocortisone hemisuccinate / hydrocortisone placebo will be given as 50 mg intravenous bolus every 6 hours;~9 alpha fludrocortisone / 9 alpha fludrocortisone placebo will be given as a 50 μg tablet via a nasogastric tube once per day in the morning.~Study drugs will be started immediately after randomization (day 0 of the study), until discharge from ICU for a maximal duration of 7 days. Study drugs will be stopped without tapering off.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Administration procedures
Description: Hydrocortisone hemisuccinate / hydrocortisone placebo will be given as 50 mg intravenous bolus every 6 hours;~9 alpha fludrocortisone / 9 alpha fludrocortisone placebo will be given as a 50 μg tablet via a nasogastric tube once per day in the morning.~Study drugs will be started immediately after randomization (day 0 of the study), until discharge from ICU for a maximal duration of 7 days. Study drugs will be stopped without tapering off.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Administration procedures
Description: Hydrocortisone hemisuccinate / hydrocortisone placebo will be given as 50 mg intravenous bolus every 6 hours;~9 alpha fludrocortisone / 9 alpha fludrocortisone placebo will be given as a 50 μg tablet via a nasogastric tube once per day in the morning.~Study drugs will be started immediately after randomization (day 0 of the study), until discharge from ICU for a maximal duration of 7 days. Study drugs will be stopped without tapering off.
Study: NCT05522686

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patients in the Brochure Education Group
Description: Patients in the Brochure Education Group were given information about urodynamics in a room reserved for education, and the education brochure was introduced. Patients reviewed the brochure and at the end of the education, it was given to them.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patients in the Video Education Group
Description: Patients in the Video Education Group were informed about urodynamics in a room reserved for education. Patients watched the educational video on a computer. The urodynamics patient education video was shown to patients once during the session. They did not request to watch it again.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patients in the Brochure-Supported Video Education Group
Description: Patients in the Brochure-Supported Video Education Group were given information about urodynamics in a room reserved for education, and the education brochure was introduced. They examined the brochure and watched the educational video on a computer.

Intervention type: OTHER
Group type: OTHER
Intervention: Control Group
Description: Patients in this group were given routine clinical information by the healthcare professional that would perform the urodynamics procedure. After patients were given verbal information, a written text containing the necessary preparations for urodynamics was given to them. The routine patient information text included adjustment to the appointment day and time, nutrition, mechanical bowel preparation, and medications necessary for the procedure.
Study: NCT06235580

Intervention type: OTHER
Intervention: Biological Samples
Description: For patients, different types of banked frozen or fresh biological samples will be used in this research:~* Blood~* Skin biopsy or other tissues (liver, muscle, brain, lung...)~* Urine~* Saliva~* Cerebrospinal fluid~* Occasionally: operative leftovers (e.g. muscle, brain, lung tissue)~In control patients, we would like to collect operative remnants of cell types involved in the inflammatory and/or neurological diseases studied in the laboratory, if these patients require surgery as part of their management, and if any biological material remains after surgery. Under the same conditions, a sample of cerebrospinal fluid could be recovered.~For unaffected relatives, a single blood sample of maximum 10 ml is taken at inclusion, and samples already taken during routine care are used.
Study: NCT05317572

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 80 mcg intrathecal morphine
Description: İntraoperative Management:~Spinal anesthesia was administered to each patient in a sitting position, after aseptic conditions were achieved with a midline approach. A 25 gauge pencil point spinal needle was placed in the L3-4 or L4-5 space. Upon aspiration of clear cerebrospinal fluid (CSF), 10 mg of hyperbaric bupivacaine, 20 mcg of fentanyl and 80 micrograms of morphine were injected into the intrathecal space together with the determined morphine doses.~Postoperative analgesia management:~Diclofenac sodium 2 × 75 mg was administered intramuscularly to all patients. All patients received iv Patient Controlled Analgesia (PCA) prepared with fentanyl postoperatively. For patients with pain VAS score of 5 or more, meperidine was administered at a rate of 25 mg each time and with a total daily dose of 200 mg.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 120 mcg intrathecal morphine
Description: İntraoperative Management:~Spinal anesthesia was administered to each patient in a sitting position, after aseptic conditions were achieved with a midline approach. A 25 gauge pencil point spinal needle was placed in the L3-4 or L4-5 space. Upon aspiration of clear cerebrospinal fluid (CSF), 10 mg of hyperbaric bupivacaine, 20 mcg of fentanyl and 120 micrograms of morphine were injected into the intrathecal space together with the determined morphine doses.~Postoperative analgesia management:~Diclofenac sodium 2 × 75 mg was administered intramuscularly to all patients. All patients received iv Patient Controlled Analgesia (PCA) prepared with fentanyl postoperatively. For patients with pain VAS score of 5 or more, meperidine was administered at a rate of 25 mg each time and with a total daily dose of 200 mg.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 160 mcg intrathecal morphine
Description: İntraoperative Management:~Spinal anesthesia was administered to each patient in a sitting position, after aseptic conditions were achieved with a midline approach. A 25 gauge pencil point spinal needle was placed in the L3-4 or L4-5 space. Upon aspiration of clear cerebrospinal fluid (CSF), 10 mg of hyperbaric bupivacaine, 20 mcg of fentanyl and 160 mcg of morphine were injected into the intrathecal space together with the determined morphine doses.~Postoperative analgesia management:~Diclofenac sodium 2 × 75 mg was administered intramuscularly to all patients. All patients received iv Patient Controlled Analgesia (PCA) prepared with fentanyl postoperatively. For patients with pain VAS score of 5 or more, meperidine was administered at a rate of 25 mg each time and with a total daily dose of 200 mg.
Study: NCT06235580

Intervention type: OTHER
Intervention: Biological Samples
Description: For patients, different types of banked frozen or fresh biological samples will be used in this research:~* Blood~* Skin biopsy or other tissues (liver, muscle, brain, lung...)~* Urine~* Saliva~* Cerebrospinal fluid~* Occasionally: operative leftovers (e.g. muscle, brain, lung tissue)~In control patients, we would like to collect operative remnants of cell types involved in the inflammatory and/or neurological diseases studied in the laboratory, if these patients require surgery as part of their management, and if any biological material remains after surgery. Under the same conditions, a sample of cerebrospinal fluid could be recovered.~For unaffected relatives, a single blood sample of maximum 10 ml is taken at inclusion, and samples already taken during routine care are used.

Intervention type: OTHER
Intervention: Biological Samples
Description: For patients, different types of banked frozen or fresh biological samples will be used in this research:~* Blood~* Skin biopsy or other tissues (liver, muscle, brain, lung...)~* Urine~* Saliva~* Cerebrospinal fluid~* Occasionally: operative leftovers (e.g. muscle, brain, lung tissue)~In control patients, we would like to collect operative remnants of cell types involved in the inflammatory and/or neurological diseases studied in the laboratory, if these patients require surgery as part of their management, and if any biological material remains after surgery. Under the same conditions, a sample of cerebrospinal fluid could be recovered.~For unaffected relatives, a single blood sample of maximum 10 ml is taken at inclusion, and samples already taken during routine care are used.